

Resource Summary Report

Generated by SPARC SAWG on Aug 7, 2026

NONMEM

RRID:SCR_016986

Type: Tool

Proper Citation

NONMEM (RRID:SCR_016986)

Resource Information

URL: <https://www.iconplc.com/innovation/nonmem/>

Proper Citation: NONMEM (RRID:SCR_016986)

Description: Software tool for nonlinear mixed effects modelling. Used for population pharmacokinetic and pharmacodynamic analysis and to simulate data and to fit data. Used in the development of new drugs. NONMEM versions up through 6 are the property of the Regents of the University of California, San Francisco, but ICON Development Solutions has exclusive rights to license their use. NONMEM 7 up to the current version is the property of ICON Development Solutions.

Abbreviations: Nonmem

Synonyms: NONMEM 7.4, NONMEM 7, Nonlinear mixed effects modelling software, NONMEM 7.2, NONlinear Mixed Effects Modeling software, population analysis

Resource Type: software resource, software application, simulation software, data analysis software, data processing software

Keywords: nonlinear, mixed, effect, modeling, pharmacokinetic, pharmacodynamic, analysis, data

Availability: Commercially available

Resource Name: NONMEM

Resource ID: SCR_016986

License: Proprietary software license

Record Creation Time: 20220129T080333+0000

Record Last Update: 20260808T042847+0000

Ratings and Alerts

No rating or validation information has been found for NONMEM.

No alerts have been found for NONMEM.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Melero I, et al. (2026) Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. *Nature cancer*, 7(5), 840.

Lin CW, et al. (2026) Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEM. *CPT: pharmacometrics & systems pharmacology*, 15(5), e70253.

Liu X, et al. (2026) Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer. *Clinical and translational science*, 19(7), e70649.

Ma Y, et al. (2025) A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. *Nature medicine*, 31(6), 1949.

Papathanasiou T, et al. (2025) Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma. *Clinical pharmacokinetics*, 64(6), 925.

Gracia M, et al. (2025) A population pharmacokinetic approach to compare ⁵¹Cr-EDTA and ^{99m}Tc-DTPA clearances in measuring renal glomerular filtration rate in oncopediatrics. *Pediatric nephrology (Berlin, Germany)*, 40(10), 3163.

Ajavon-Hartmann A, et al. (2025) Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart Disease. *Clinical pharmacology and therapeutics*, 118(2), 365.

Chow T, et al. (2025) Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response Analyses. *Clinical pharmacology and therapeutics*, 118(2), 449.

Jin Y, et al. (2025) Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma. *Clinical pharmacokinetics*, 64(8), 1231.

Cortés J, et al. (2025) A First-in-Class mAb (BI-1607) Targeting Fc γ RIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(23), 4953.

Li C, et al. (2025) Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(11), 2115.

Chandasana H, et al. (2023) Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents. *Clinical pharmacokinetics*, 62(10), 1445.

Subbiah V, et al. (2023) Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(16), 2988.

Björnsson M, et al. (2023) Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder. *Clinical pharmacokinetics*, 62(10), 1427.

Morcos PN, et al. (2023) Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab. *CPT: pharmacometrics & systems pharmacology*, 12(11), 1666.

Yang L, et al. (2023) A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid (CB1) receptor. *British journal of pharmacology*, 180(20), 2661.

Perlstein I, et al. (2022) Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone. *Clinical pharmacology in drug development*, 11(7), 865.

Tanneau L, et al. (2022) Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. *Clinical pharmacokinetics*, 61(8), 1177.

Martínez-López J, et al. (2022) Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia. *Medicine international*, 2(2), 7.

Scarpignato C, et al. (2022) A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure. *Journal of clinical pharmacology*, 62(6), 801.